Counts describe this library, not the strength of evidence.
Cómo interpretar la evidencia
Separate prevention outcomes, risk-factor changes and screening performance. A drug trial in established disease, an exercise blood-pressure analysis and a smartwatch alert study cannot be treated as equivalent evidence for a healthy individual.
In 8639 people from the Whitehall II cohort, systolic blood pressure of 130 mmHg or higher at age 50 was linked to a higher dementia risk (HR 1.38; 95% CI 1.11, 1.70), but no link was seen at age 60 or 70. This is an observational association with dementia recorded from health records, so it does not show that lowering blood pressure at 50 prevents dementia.
Across 20 cohort articles (361 254 people, 90 160 new hypertension cases), men drinking 1 to 2 drinks a day had higher hypertension risk than abstainers (RR 1.19, 95% CI 1.07-1.31), while women at that level did not (RR 0.94, 0.88-1.01). These are observational cohort data, so they show association and cannot prove the sex difference is biological.
In 163 overweight or obese adults who trained for 8 months, those who lost at least 3% of body weight improved insulin sensitivity by 2.2 mU·l-1·min-1 (CI 1.5 to 2.8), against 0.8 (CI 0.5 to 1.2) in those who lost less. Groups were defined by the weight loss achieved, not randomised, so other differences between them may play a part.
In 1182 UK adults with poorly controlled hypertension, home self-monitoring to guide medication changed 12-month systolic pressure by -3.5 mm Hg versus usual care (95% CI -5.8 to -1.2), and adding telemonitoring by -4.7 mm Hg (95% CI -7.0 to -2.4). The trial was unmasked and 15% were missing from the main analysis.
In a UK primary care database, 9,118 women with gestational diabetes had far higher rates of later type 2 diabetes (IRR 21.96) and hypertension (IRR 1.85) than 37,281 matched women, and a higher rate of ischemic heart disease (IRR 2.78, 95% CI 1.37-5.66). The heart disease finding rests on few events over short follow-up, so its size is uncertain.
In 100 patients with obesity and hypertension, 83.7% (41 of 49) of those randomized to gastric bypass plus medication cut their antihypertensive drugs by at least 30% while keeping blood pressure controlled at 12 months, versus 12.8% (6 of 47) on medication alone (rate ratio 6.6, 95% CI 3.1-14.0). It was a single-center, unblinded trial with one year of follow-up, so long-term effects and safety are not shown here.
In 15,222 adults followed for a median 19.7 years, each decade of abstaining from alcohol was linked to an approximately 20% lower rate of atrial fibrillation (AF; 95% CI 11-28%). It is an observational cohort, and former drinkers actually had a higher AF rate than lifetime abstainers, so it cannot show that quitting itself lowers risk.
In a cross-sectional study of men in China, adjusted diastolic pressure and mean arterial pressure were lower in current smokers than nonsmokers (P < 0.05), while former smokers had higher odds of hypertension than never smokers (OR 1.48, 95% CI 1.01 to 2.18). A one-time snapshot cannot say whether smoking or quitting changed blood pressure.
In an individual patient data meta-analysis of randomised trials, self-monitoring reduced clinic systolic blood pressure (-3.2 mmHg; 95% CI -4.9 to -1.6) at 12 months, but monitoring alone showed no clear effect (-1.0 mmHg; 95% CI -3.3 to 1.2). Heterogeneity between trials remained large, so effects in any one setting may differ.
Among 4686 people followed for 9 years, 2047 developed hypertension, and the 9-year incidence rose from 28.5% in the lowest quarter of the triglyceride-glucose (TyG) index to 59.8% in the highest (p for trend < 0.001). This is an association in one Chinese cohort, and the abstract gives no adjusted risk estimates or the factors that were adjusted for.
Pooling 7 prospective cohorts (205,349 people, 44,120 hypertension cases), each extra daily cup of coffee was linked to a 1% lower risk of new hypertension, and 7 cups a day to a 9% lower risk in the non-linear model. This is observational, and smoking-related variables weakened the association, so other habits may play a part.
In 763 overweight adults on a 4-month phone-based coaching program, weight fell an average of 3.23%, and 28.6% (218/763) lost 5% or more of body weight. There was no randomised control group, only 73 people compared with their own weight before coaching, so the results cannot separate coaching from other influences.
In 27,564 people with atherosclerotic cardiovascular disease already on a statin, adding evolocumab lowered LDL cholesterol by 59% versus placebo at 48 weeks and reduced the primary composite of cardiovascular events to 9.8% from 11.3% over a median 2.2 years (HR 0.85, 95% CI 0.79 to 0.92). Amgen funded the trial, follow-up was short, and only people with established disease took part, so the result does not speak to healthy people or to long-term safety.
In 1231 adolescents aged 14-17, a higher resting heart rate went with higher systolic and diastolic blood pressure in both boys and girls, even after accounting for general and abdominal obesity. This is a one-time cross-sectional snapshot, so it cannot show which of the two drives the other.
Across 23 placebo-controlled trials with 1213 participants, oral potassium lowered systolic blood pressure by 4.25 mm Hg (95% CI -5.96 to -2.53) and diastolic by 2.53 mm Hg versus placebo in primary hypertension. The trials differed noticeably on the diastolic result (I2 = 65%), and the abstract's safety claim comes with no adverse-event numbers.
In 76 patients with paroxysmal or persistent atrial fibrillation, 12 weeks of high-intensity exercise did not change AF burden differently from low-intensity exercise (incidence rate ratio 0.742, 95% CI 0.29-1.91, P=0.538). Only 63 finished and the interval is wide, so a real difference in either direction cannot be ruled out.